Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G C Jayson

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|March 27, 2001
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphomaF H Blackhall, M Ranson, J A Radford, et al.
Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.
Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association|February 7, 2020
Dealing with loss: food and eating in women with ovarian cancer on parenteral nutritionA M Sowerbutts, S Lal, J Sremanakova, et al.
British Journal of Cancer|January 13, 2006
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancerA R Clamp, J Mäenpää, D Cruickshank, et al.
British Journal of Cancer|March 25, 2000
Requirement for expert histopathological assessment of ovarian cancer and borderline tumorsP S Sengupta, J H Shanks, C H Buckley, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2007
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinomaD D Rosa, N C Ton, A Clamp, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2007
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerA R Clamp, P Schöffski, J W Valle, et al.
Journal of Cancer Research and Clinical Oncology|October 27, 2005
Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factorM K Whitworth, A Sheen, D D Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
p53 and related proteins in epithelial ovarian cancerP S Sengupta, A T McGown, V Bajaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancerM Zweifel, G C Jayson, N S Reed, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|March 27, 2001
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphomaF H Blackhall, M Ranson, J A Radford, et al.
Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.
Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association|February 7, 2020
Dealing with loss: food and eating in women with ovarian cancer on parenteral nutritionA M Sowerbutts, S Lal, J Sremanakova, et al.
British Journal of Cancer|January 13, 2006
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancerA R Clamp, J Mäenpää, D Cruickshank, et al.
British Journal of Cancer|March 25, 2000
Requirement for expert histopathological assessment of ovarian cancer and borderline tumorsP S Sengupta, J H Shanks, C H Buckley, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2007
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinomaD D Rosa, N C Ton, A Clamp, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2007
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerA R Clamp, P Schöffski, J W Valle, et al.
Journal of Cancer Research and Clinical Oncology|October 27, 2005
Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factorM K Whitworth, A Sheen, D D Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
p53 and related proteins in epithelial ovarian cancerP S Sengupta, A T McGown, V Bajaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancerM Zweifel, G C Jayson, N S Reed, et al.
Pageof 7